PL2361620T3 - Zastosowanie aminosalicylanów w zespole jelita drażliwego z dominującą postacią biegunkową - Google Patents

Zastosowanie aminosalicylanów w zespole jelita drażliwego z dominującą postacią biegunkową

Info

Publication number
PL2361620T3
PL2361620T3 PL11000447.0T PL11000447T PL2361620T3 PL 2361620 T3 PL2361620 T3 PL 2361620T3 PL 11000447 T PL11000447 T PL 11000447T PL 2361620 T3 PL2361620 T3 PL 2361620T3
Authority
PL
Poland
Prior art keywords
diarrhoea
asa
bowel syndrome
irritable bowel
predominant irritable
Prior art date
Application number
PL11000447.0T
Other languages
English (en)
Polish (pl)
Inventor
Nicolas Peter Shortis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004900563A external-priority patent/AU2004900563A0/en
Application filed filed Critical
Publication of PL2361620T3 publication Critical patent/PL2361620T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL11000447.0T 2004-02-06 2005-02-04 Zastosowanie aminosalicylanów w zespole jelita drażliwego z dominującą postacią biegunkową PL2361620T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2004900563A AU2004900563A0 (en) 2004-02-06 Use of Aminosalicylates in Diarrhoea-Predominant Irritable Bowel Syndrome

Publications (1)

Publication Number Publication Date
PL2361620T3 true PL2361620T3 (pl) 2016-12-30

Family

ID=34831684

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11000447.0T PL2361620T3 (pl) 2004-02-06 2005-02-04 Zastosowanie aminosalicylanów w zespole jelita drażliwego z dominującą postacią biegunkową

Country Status (12)

Country Link
US (5) US20070213304A1 (enExample)
EP (2) EP2361620B1 (enExample)
JP (2) JP2007520495A (enExample)
AT (1) ATE554752T1 (enExample)
AU (1) AU2005209948B2 (enExample)
CA (1) CA2555304C (enExample)
ES (1) ES2571252T3 (enExample)
HU (1) HUE029189T2 (enExample)
NZ (1) NZ549661A (enExample)
PL (1) PL2361620T3 (enExample)
WO (1) WO2005074908A1 (enExample)
ZA (1) ZA200607435B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029189T2 (en) 2004-02-06 2017-02-28 Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome
EP2586427A3 (en) * 2005-08-24 2013-05-29 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
RU2297835C1 (ru) * 2005-09-26 2007-04-27 Закрытое акционерное общество "Партнер" Препарат для лечения неинфекционных воспалительных болезней кишечника
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
NZ598716A (en) 2009-10-26 2014-08-29 Borody Thomas J Novel enteric combination therapy

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791889A (fr) 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4298595A (en) 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4960765A (en) 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
JPS57500432A (enExample) 1980-03-20 1982-03-11
EP0039306B1 (de) 1980-03-28 1984-01-11 Ciba-Geigy Ag Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
US4412922A (en) 1980-07-02 1983-11-01 Abcor, Inc. Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4562024A (en) 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
US4558552A (en) * 1983-07-08 1985-12-17 Reitter Stucco, Inc. Building panel and process for making
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
SE8405924L (sv) 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US4781925A (en) 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5374430A (en) 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
DE3887353T2 (de) 1987-10-12 1994-05-05 Capability Services Pty Ltd Behandlungsverfahren für magen-darm-krankheiten.
US5064637A (en) 1989-05-30 1991-11-12 Board Of Regents, The University Of Texas System Substituted sulfonamide derivatives which inhibit allergic reactions
US5095073A (en) 1990-03-02 1992-03-10 Exxon Research And Engineering Company Water soluble rigid rod sulfonated aromatic polyamide
SE9003296L (sv) 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
AU652191B2 (en) * 1990-10-22 1994-08-18 Centre For Digestive Diseases Pty Ltd Treatment of non-inflammatory and non-infectious bowel disorders
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
JP3425441B2 (ja) * 1990-10-22 2003-07-14 ガストロ サービシイズ ピーティーワイ リミテッド 非炎症性及び非感染性腸障害の処置
WO1992016214A1 (en) * 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
DE59307753D1 (de) 1992-03-11 1998-01-15 Asta Medica Ag Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
JPH08169847A (ja) 1994-12-16 1996-07-02 Morishita Roussel Kk 固形製剤
US5905073A (en) 1995-01-06 1999-05-18 Salix Pharmaceuticals, Inc. Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
SE9700934D0 (sv) 1997-03-14 1997-03-14 Astra Ab New formulation
WO1998043667A1 (en) 1997-04-01 1998-10-08 Borody Thomas J Methods and compositions for treating inflammatory bowel disease
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
US20030078205A1 (en) 2001-07-31 2003-04-24 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6144381A (en) 1997-05-14 2000-11-07 International Business Machines Corporation Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6489447B1 (en) 1998-05-06 2002-12-03 Genentech, Inc. Protein purification
US5927500A (en) 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
EP1098634A4 (en) 1998-07-20 2006-10-25 Smithkline Beecham Corp EPROSARTAN CONTAINING MORE EFFECTIVE FORMULATIONS IN ORAL SOLID PHARMACEUTICAL FORM
KR20000011247A (ko) 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20030138399A1 (en) 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
CA2420576C (en) 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
CA2421114C (en) * 2000-08-29 2010-12-07 Nobex Corporation 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
US6562871B1 (en) 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AU2003226752A1 (en) 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine base
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
JPWO2004082715A1 (ja) 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
WO2005030173A1 (en) * 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
HUE029189T2 (en) 2004-02-06 2017-02-28 Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome
EP2586427A3 (en) 2005-08-24 2013-05-29 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2008033125A1 (en) 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate

Also Published As

Publication number Publication date
AU2005209948A1 (en) 2005-08-18
HUE029189T2 (en) 2017-02-28
US20130231308A1 (en) 2013-09-05
ZA200607435B (en) 2009-05-27
EP1720536A4 (en) 2008-03-05
US10328088B2 (en) 2019-06-25
US20070213304A1 (en) 2007-09-13
ES2571252T3 (es) 2016-05-24
EP2361620B1 (en) 2016-04-06
WO2005074908A1 (en) 2005-08-18
AU2005209948B2 (en) 2009-09-10
EP2361620A1 (en) 2011-08-31
JP5558456B2 (ja) 2014-07-23
CA2555304A1 (en) 2005-08-18
NZ549661A (en) 2010-07-30
US20200101090A1 (en) 2020-04-02
JP2007520495A (ja) 2007-07-26
CA2555304C (en) 2016-06-28
US20150164923A1 (en) 2015-06-18
US9937190B2 (en) 2018-04-10
US20180250315A1 (en) 2018-09-06
EP1720536B1 (en) 2012-04-25
ATE554752T1 (de) 2012-05-15
JP2012102112A (ja) 2012-05-31
EP1720536A1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
PT1522314E (pt) Medicamentos para doenças causadas pela contracção ou dilatação vascular
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
EA200501936A1 (ru) Производные пиридо[2,1-a]изохинолина в качестве ингибиторов dpp-iv
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006113942A3 (en) Method of inhibiting cathepsin activity
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
SG135192A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MX2020009511A (es) Tratamiento o prevención de eventos cardiovasculares.
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
CY1108367T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
DE60333605D1 (de) Tuberkulosebehandlung mit Pleuromutilinderivaten
TNSN07419A1 (en) Methods for treating drug resistant cancer
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
ZA200607435B (en) Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
UY28006A1 (es) Agonistas ppar quirales
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
TW200742580A (en) Methods for treating nephrolithiasis
EA200600115A1 (ru) Производные 2-аминобензойной кислоты